What is he best known for?
The fields of study Roberto Labianca is best known for:
- Cancer
- Chemotherapy
- Clinical trial
The study of Irinotecan, Oxaliplatin and KRAS are components of his Colorectal cancer research.
Roberto Labianca merges many fields, such as Internal medicine and Pathology, in his writings.
Pathology and Internal medicine are two areas of study in which Roberto Labianca engages in interdisciplinary research.
With his scientific publications, his incorporates both Cancer and Performance status.
In most of his Oncology studies, his work intersects topics such as Adjuvant.
He combines Chemotherapy and Fluorouracil in his research.
His Surgery study frequently draws connections to adjacent fields such as Fluorouracil.
Roberto Labianca undertakes multidisciplinary studies into Randomized controlled trial and Clinical endpoint in his work.
He regularly links together related areas like Surgery in his Clinical endpoint studies.
His most cited work include:
- Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer (1234 citations)
- Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial (972 citations)
- Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer (936 citations)
What are the main themes of his work throughout his whole career to date
Fluorouracil and Cisplatin are the two main areas of interest in his Chemotherapy studies.
Roberto Labianca applies his multidisciplinary studies on Fluorouracil and Colorectal cancer in his research.
He merges Colorectal cancer with Oxaliplatin in his research.
He performs multidisciplinary study in Cisplatin and Chemotherapy in his work.
In his articles, Roberto Labianca combines various disciplines, including Internal medicine and Intensive care medicine.
Roberto Labianca performs integrative study on Intensive care medicine and Internal medicine.
Roberto Labianca performs multidisciplinary study on Cancer and Disease in his works.
He carries out multidisciplinary research, doing studies in Disease and Cancer.
Roberto Labianca integrates several fields in his works, including Oncology and Gastroenterology.
Roberto Labianca most often published in these fields:
- Internal medicine (97.52%)
- Cancer (81.37%)
- Oncology (64.60%)
What were the highlights of his more recent work (between 2018-2022)?
- Internal medicine (100.00%)
- Cancer (94.12%)
- Oncology (88.24%)
In recent works Roberto Labianca was focusing on the following fields of study:
Internal medicine is frequently linked to Platelet in his study.
Roberto Labianca conducted interdisciplinary study in his works that combined Cancer and Breast cancer.
With his scientific publications, his incorporates both Breast cancer and Cancer.
He incorporates Oncology and Gastroenterology in his studies.
Borrowing concepts from Oncology, he weaves in ideas under Gastroenterology.
Roberto Labianca integrates many fields in his works, including Colorectal cancer and Capecitabine.
He integrates Capecitabine with Colorectal cancer in his study.
Roberto Labianca integrates Oxaliplatin and Chemotherapy in his research.
He integrates Chemotherapy with FOLFOX in his study.
Between 2018 and 2022, his most popular works were:
- Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials (113 citations)
- Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer (44 citations)
- Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin (28 citations)
In his most recent research, the most cited works focused on:
- Cancer
- Chemotherapy
- Clinical trial
Roberto Labianca undertakes interdisciplinary study in the fields of Oxaliplatin and Capecitabine through his research.
Roberto Labianca combines Capecitabine and Colorectal cancer in his studies.
With his scientific publications, his incorporates both Colorectal cancer and Fluorouracil.
Fluorouracil and Oxaliplatin are two areas of study in which he engages in interdisciplinary research.
Roberto Labianca performs multidisciplinary study in Hazard ratio and Confidence interval in his work.
Roberto Labianca incorporates Confidence interval and Hazard ratio in his studies.
His study connects Adverse effect and Internal medicine.
He performs integrative Adverse effect and Cancer research in his work.
He performs multidisciplinary study in Cancer and Randomized controlled trial in his work.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
